<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404298</url>
  </required_header>
  <id_info>
    <org_study_id>P111122</org_study_id>
    <nct_id>NCT02404298</nct_id>
  </id_info>
  <brief_title>Transcriptome Analysis of the Peripheral Blood in CIDP</brief_title>
  <acronym>PHARMACOPID</acronym>
  <official_title>Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated
      disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy
      for CIDP. The investigators used a transcriptomic approach to compare the gene expression
      profiles in the peripheral blood of patients having a CIDP or autoimmune diseases, before and
      after IVIg treatment, in order to identify their mechanism of action in this condition, to
      lead to a better understanding of CIDP pathophysiology, and potentially determine factors
      associated with the response to the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We study the change of the:

        -  gene profile on transcriptome analysis of peripheral blood

        -  T cell repertory

        -  igG dosage

        -  immunological profile

      Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of
      patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune
      diseases.

      We also search for polymorphism of FCgammareceptor, TKPC et CASP3 genes in CIDP patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression profile</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expression profile in each lymphocytary sub-group</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2), in each lymphocytary sub-group : CD3+CD4+, CD3+CD8+, CD4+FoxP3+, CD4+CD25+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG</measure>
    <time_frame>3 weeks</time_frame>
    <description>To measure IgG in a peripheral blood sample at T1 and T2 time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Clarkson Syndrome</condition>
  <condition>Muscular Autoimmune Disorders</condition>
  <arm_group>
    <arm_group_label>IVIg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIg</intervention_name>
    <arm_group_label>IVIg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Age ≥ 18 years old

          -  Obtained informed consent

          -  Patient having a definite or probable CIDP according to EFNS/PNS criteria or atypical
             CIDP corresponding to patients having the EFNS/PNS clinical criteria and at least two
             EFNS/PNS supportive criteria

          -  Or

          -  Patient having a muscular autoimmune disease, or a Clarkson syndrome or other
             autoimmune disease

          -  Currently treated by IVIG

        Exclusion criteria :

          -  pregnancy

          -  breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Viala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karine Viala, MD</last_name>
    <phone>01 42 16 19 45</phone>
    <email>karine.viala@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grooupe Hospitalier Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Viala, MD</last_name>
      <phone>+331 42 16 19 45</phone>
      <email>karine.viala@psl.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcriptome analysis</keyword>
  <keyword>peripheral blood</keyword>
  <keyword>chronic inflammatory demyelinating polyradiculoneuropathy</keyword>
  <keyword>auto immune diseases</keyword>
  <keyword>IVIg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

